# OnCo record paper-geometry-mono-1-capmatinib-nejm-2020 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-geometry-mono-1-capmatinib-nejm-2020/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-geometry-mono-1-capmatinib-nejm-2020" ;
  schema:name "GEOMETRY mono-1: capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer"@en ;
  schema:description "The MET inhibitor capmatinib shrank tumours in two thirds of untreated and four in ten previously treated patients with MET exon 14-skipping lung cancer, leading to the first approval for this driver, while MET-amplified tumours responded only at very high copy number."@en ;
  schema:url <https://onco.cc/key-papers/paper-geometry-mono-1-capmatinib-nejm-2020/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2002787>, <https://pubmed.ncbi.nlm.nih.gov/32877583/> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa2002787> ;
  schema:datePublished "2020"^^xsd:gYear ;
  schema:author "Wolf J, Seto T, Han JY, et al." ;
  onco:cancers <https://onco.cc/cancers/met-altered-nsclc/> ;
  onco:drugs <https://onco.cc/drugs/capmatinib/> ;
  onco:trials <https://onco.cc/trials/geometry-mono-1/> ;
  onco:journals <https://onco.cc/journals/nejm/> .